1. Scrip
  2. >>Business

AbClon Shines On Korean Debut Amid Robust Investor Interest

 
• By Jung Won Shin

AbClon has made a strong debut on the Kosdaq market with investors backing the innovative antibody drug firm in a year where IPOs by South Korean novel drug developers have been generally scarce.

Global currency

Shares of the South Korea-based AbClon Inc surged on their debut on the Kosdaq market aided by the encouraging outlook for its broad antibody pipeline and platform technology as well as recent positive market sentiment towards pharma/biotech stocks. shines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.